About: Impact of apolipoprotein A5 variants on statin treatment efficacy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Impact of apolipoprotein A5 variants on statin treatment efficacy Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Despite the fact that the statin treatment efficacy is very high, there are substantial differences in effects between treated individuals. It is supposed the genetic predisposition plays an important role in these differences but roles of individual polymorphisms are poorly understood. So far, as many as about thirty genes have been examined with ambiguous results. Apolipoprotein A5 is an important determinant of plasma lipid concentration and its genetic variation could account for some of the observed differences in the response to statin therapy. However, this has not been analyzed so far. We examined the putative association between APOA5 SNPs (T-1131C, Ser19Trp and Val153Met) and efficacy of three months of statin treatment in 188 Caucasians. Carriers of the APOA5 genotype TT-1131 benefited more from statin treatment in comparison to the C-1131 allele carriers ( LDL-C -36.3?15.1% vs. LDL-C -29.9?12.5%; P<0.005, Mann-Whitney test). Our results suggest that the APOA5 gene variations may play a Despite the fact that the statin treatment efficacy is very high, there are substantial differences in effects between treated individuals. It is supposed the genetic predisposition plays an important role in these differences but roles of individual polymorphisms are poorly understood. So far, as many as about thirty genes have been examined with ambiguous results. Apolipoprotein A5 is an important determinant of plasma lipid concentration and its genetic variation could account for some of the observed differences in the response to statin therapy. However, this has not been analyzed so far. We examined the putative association between APOA5 SNPs (T-1131C, Ser19Trp and Val153Met) and efficacy of three months of statin treatment in 188 Caucasians. Carriers of the APOA5 genotype TT-1131 benefited more from statin treatment in comparison to the C-1131 allele carriers ( LDL-C -36.3?15.1% vs. LDL-C -29.9?12.5%; P<0.005, Mann-Whitney test). Our results suggest that the APOA5 gene variations may play a (en)
Title	Impact of apolipoprotein A5 variants on statin treatment efficacy Impact of apolipoprotein A5 variants on statin treatment efficacy (en)
skos:prefLabel	Impact of apolipoprotein A5 variants on statin treatment efficacy Impact of apolipoprotein A5 variants on statin treatment efficacy (en)
skos:notation	RIV/00023001:_____/09:00001969!RIV10-MZ0-00023001
http://linked.open...avai/riv/aktivita	P V
http://linked.open...avai/riv/aktivity	P(1M0510), P(NR9411), V
http://linked.open...iv/cisloPeriodika	6
http://linked.open...vai/riv/dodaniDat	2010
http://linked.open...aciTvurceVysledku	Hubáček, Jaroslav Lánská, Věra Adámková, Věra
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Institut klinické a experimentální medicíny
http://linked.open...dnocenehoVysledku	318570
http://linked.open...ai/riv/idVysledku	RIV/00023001:_____/09:00001969
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	apolipoprotein A5; polymorphism; statin; cholesterol; efficacy (en)
http://linked.open.../riv/klicoveSlovo	apolipoprotein A5 efficacy cholesterol polymorphism statin
http://linked.open...odStatuVydavatele	GB - Spojené království Velké Británie a Severního Irska
http://linked.open...ontrolniKodProRIV	[19BF661454A0]
http://linked.open...i/riv/nazevZdroje	Pharmacogenomics
http://linked.open...in/vavai/riv/obor	FA
http://linked.open...ichTvurcuVysledku	3 (xsd:int)
http://linked.open...cetTvurcuVysledku	8 (xsd:int)
http://linked.open...vavai/riv/projekt	Genetic determination of the hypolipidemic treatment efficacy Centre for cardiovascular research
http://linked.open...UplatneniVysledku	2009
http://linked.open...v/svazekPeriodika	10
http://linked.open...iv/tvurceVysledku	Adámková, Věra Hubáček, Jaroslav Lánská, Věra Snejdrlova, M. Vrablik, M. Češka, R. Hirschfeldova, K. Prusiková, M.
http://linked.open...ain/vavai/riv/wos	000267815800003
issn	1462-2416
number of pages	6 (xsd:int)
is http://linked.open...avai/riv/vysledek of	Impact of apolipoprotein A5 variants on statin treatment efficacy Impact of apolipoprotein A5 variants on statin treatment efficacy Impact of apolipoprotein A5 variants on statin treatment efficacy Impact of apolipoprotein A5 variants on statin treatment efficacy

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 35 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software